posted on 01 Jul 2019
Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye disease, today reports positive topline data from a Phase 1 study with THR-149, a novel, potent, plasma kallikrein (PKal) inhibitor for the treatment of Diabetic Macular Edema (DME).
THR-149 has been developed in partnership with Bicycle Therapeutics (Nasdaq: BCYC).
The Phase 1 open-label, multicenter (US), non-randomized trial evaluated the safety of a single intravitreal (IVT) injection of THR-149, a novel PKal inhibitor, at 3 ascending dose levels in 12 subjects with visual impairment due to center-involved DME (CI-DME) (NCT03511898).
Topline data from the trial show that THR-149 is well-tolerated and safe. No dose-limiting toxicities nor drug-related serious adverse events were reported at any of the dosages evaluated in the study.
For more details, please see the article here
Geek+, a global AMR leader is pleased to announce it has extended its cooperation with Decathlon, one of the world's largest retailers of sporting goods, present in over 50 countries with more than 1,600 stores globally. Following the success of a two-year collaboration in its e-commerce and retail fulfillment centers in Shanghai, Decathlon accelerated its automation program, with AMR deployments at two new sites in China. The installations were successfully deployed remotely in under 3 months, following strict pandemic restrictions.
Geek+, a global AMR leader, announces its commitment to provide smart logistics solutions for enabling efficient and flexible operations to Winit, an integrated supply chain solutions provider for cross-border e-commerce serving industry leaders like eBay, for its fulfillment center located Cincinnati, Ohio.
Rick DeFiesta, Director of Business Development and Partnership at Geek+, said: "We are pleased that Winit has chosen our Goods-to-Person solution for optimizing their warehouse operations and we are confident that our P-series robots will exceed expectation to increase picking efficiency, simplify processes, and reduce management issues."
“Sir Keith is a world-renowned expert in the field of clinical immunology and has made significant contributions to the development of new medicines by applying a better understanding of physiology to the development of novel therapies,” said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics.